• Text in Japanese

2019-01-15

Publish  Clinical Cancer Research

Osaka University researchers base biomarker detection and targeted therapy on the same protein from pancreatic cancer patients

Fig.1: DKK1–CKAP4 signaling and application of the anti-CKAP4 antibody
DKK1 and CKAP4 are overexpressed in cancer cells and the PI3 kinase–AKT pathway is activated, promoting cell proliferation. Cancer cells secrete CKAP4 in exosomes, and serum CKAP4 is detected by the anti-CKAP4 antibody as a biomarker of pancreatic cancer. The anti-CKAP4 antibody is also useful in pancreatic cancer therapy.

Of all gastrointestinal cancers, pancreatic cancer is one of the most aggressive. Because of this, it has a very low 5-year survival rate of just 5% and a median survival time below 6 months. Additionally, treatment is difficult, with only surgery shown to provide a cure. However, the vast majority of patients have tumors that cannot be removed surgically or their cancer is too advanced or spread too far to be treatable.

Current chemotherapy for pancreatic cancer is ineffective long-term. Therefore, to improve the prognosis and as a novel treatment, Osaka University researchers identified a marker protein that could be used in molecular targeted therapy and companion diagnostics. Such a tool can determine how suitable a treatment is for a specific patient, enabling tailored therapy to be administered.

The team studied CKAP4, a plasma membrane protein that functions as a receptor for the secreted protein DKK1 and promotes tumorigenesis. They found that CKAP4 was released from pancreatic cancer cells in exosomes, which are tiny membranous sacs produced by tumor cells to communicate with each other. An advantage of secreted membranous proteins is that they are fairly simple to detect because of their accessibility, so two related techniques were developed to do just this.

“We generated anti-CKAP4 monoclonal antibodies that we used to develop ELISAs for the detection of CKAP4 released by tumors,” says first author Hirokazu Kimura. “These were successfully able to measure CKAP4 protein in the serum of pancreatic cancer patients, and expression levels were shown to match those determined in the tumors themselves.”

These same monoclonal antibodies had the added advantages of blocking signaling in pancreatic tumor cells and preventing them from proliferating and migrating in the laboratory. The team then analyzed the effects of the antibodies on mouse tumors that had developed from the transplantation of human pancreatic cancer cells. Some of the antibodies inhibited tumor growth and stopped the spread of tumors to the lymph nodes, thus crucially prolonging the life of the mice.

“Our work on developing monoclonal antibody preparations against pancreatic cancer offers the dual benefits of diagnosing and treating the disease,” explains corresponding author Akira Kikuchi. “As a next step, we hope to develop screening methods for patients carrying the CKAP4 antigen biomarker who will benefit from therapeutic interventions using anti-CKAP4 antibodies.”

The article, “CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy” was published in Clinical Cancer Research at DOI: https://doi.org/10.1158/1078-0432.CCR-18-2124

Fig.2: DKK1–CKAP4 signaling and application of the anti-CKAP4 antibody
DKK1 and CKAP4 are overexpressed in cancer cells and the PI3 kinase–AKT pathway is activated, promoting cell proliferation. Cancer cells secrete CKAP4 in exosomes, and serum CKAP4 is detected by the anti-CKAP4 antibody as a biomarker of pancreatic cancer. The anti-CKAP4 antibody is also useful in pancreatic cancer therapy.

Article: CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreaticcancer and a molecular target for therapy
Journal: Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-18-2124
Authors: Hirokazu Kimura, Hideki Yamamoto, Takeshi Harada, Katsumi Fumoto, Yoshihito Osugi, Ryota Sada, Natsumi Maehara, Hayato Hikita, Soichiro Mori, Hidetoshi Eguchi, Masahito Ikawa, Tetsuo Takehara, and Akira Kikuchi
Funding: Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan Agency for Medical Research and development (AMED)
Summary:
Osaka University researchers developed monoclonal antibodies against CKAP4—a plasma membrane protein—and found that it was released from pancreatic cancer cells The antibodies not only detected CKAP4 expression as a biomarker from patient sera, but also prevented pancreatic tumor cell proliferation and suppressed tumor formation and metastasis in mice, extending their survival time. These findings are clinically important for the future development of molecular targeted therapy and companion diagnostics for pancreatic cancer.
Primary Keyword: Medicine/Health
Additional Keywords: Cancer, Molecular Biology, Biochemistry
Categories: Medical, Life Sciences